Postmenopausal breast cancer: is the short-term pain worth the long-term gain?

Publisher Website

1 April 1996

journal article
editorial
Published by Elsevier in The Lancet

Vol. 347 (9008) , 1057-1058
https://doi.org/10.1016/s0140-6736(96)90271-8

Abstract

No abstract available

Keywords

This publication has 1 reference indexed in Scilit:

Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15.
Journal of Clinical Oncology, 1990